Document is current
Any future updates will be listed below
-
Authors
Phuong, Huong T.
Tomas, Rodrigo F.
Akmese, Cemal
Mijares, Ana
Gerstin, Isabella M.
Guo, Shu
Bell, Logan R.
Ellwood, Ross
Yegorova, Svitlana
Ng, Stefani K.
Massey, Grace
Phillips, Jennifer
Melloni, Alexandra
Pletnikova, Olga
Lou, XiangYang
Clark, H. Brent
Troncoso, Juan C.
Hyman, Bradley T.
Prokop, Stefan
Ranum, Laura P. W.
Nguyen, Lien
-
Funding
Funding for this research was provided by:
National Institutes of Health
National Institutes of Health, United States
- License Information
-
More Information
Article History
Received: 30 June 2025
Revised: 25 October 2025
Accepted: 27 October 2025
First Online: 8 November 2025
Declarations
:
: Dr. H Brent Clark served as a consultant for Janssen Research and Development in 2021 and 2022.Dr. Bradley Hyman serves on the SAB of Dewpoint and has an option for stock. Dr. Bradley Hyman serves on a scientific advisory board or is a consultant for AbbVie, Alexion, Ambagon, Aprinoia Therapeutics, Arvinas, Avrobio, AstraZeneca, Biogen, Bioinsights, BMS, Cure Alz Fund, Cell Signaling, Dewpoint, Latus, Novartis, Pfizer, Sanofi, Sofinnova, Vigil, Violet, Voyager, WaveBreak. Dr. Bradley Hyman has an option for stock in Dewpoint. Dr. Bradley Hyman owns stock in Novartis. Dr. Laura Ranum is an inventor on patents that are related to RAN translation. Dr. Lien Nguyen is an inventor on patents that are related to RAN translation.
